Premium
PROSTANOID CONCENTRATIONS IN HUMAN CSF FOLLOWING ACUTE ISCHAEMIC BRAIN INFARCTION
Author(s) -
Fagan S. C.,
Castellani D.,
Gengo F. M.
Publication year - 1986
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1986.tb00948.x
Subject(s) - thromboxane , prostacyclin , medicine , cerebrospinal fluid , cerebral blood flow , animal studies , stroke (engine) , thromboxane a2 , ischaemic stroke , thromboxane b2 , prostanoid , cerebral infarction , thromboxane a synthase , pathophysiology , anesthesia , cardiology , prostaglandin , ischemia , platelet , mechanical engineering , engineering
SUMMARY 1. Thromboxane A 2 and prostacyclin are two compounds which have been implicated as important modulators of local cerebral blood flow. 2. Concentrations of the stable metabolites of these two compounds, thromboxane B 2 and 6‐keto‐PGF 1 α, were measured in cerebrospinal fluid (CSF) from eight acute ischaemic stroke patients and 14 patients with no evidence of cerebrovascular disease. 3. Concentrations of thromboxane B 2 ranged from 0.15 to 4.0 pg/ml and were significantly higher ( P = 0.025) in the ischaemic stroke group when compared with the control group (0.1–0.3 pg/ml). Simultaneously acquired concentrations of 6‐keto‐PGF 1 α were not elevated in the stroke group when compared to normals. 4. These clinical findings support evidence from animal studies that emphasizes the importance of cerebral prostaglandins in mediating the secondary vascular changes of cerebral infarction. In conclusion there is an aberration in CSF thromboxane B 2 concentrations in patients who have had a stroke. This may be an acute or chronic phenomenon.